ALA-3000 vs Esketamine (CLE-100)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

ALA-3000

Developed by Alar Pharmaceuticals

Phase 1 in Major Depressive Disordersmall molecule
Partial signal

NCT06965569 · Phase 1 · completed

This randomized, double-blind, placebo-controlled multiple-dose study gave subcutaneous ALA-3000 or placebo, with a standard oral antidepressant, to patients with treatment-resistant depression. All of its primary measures were safety and tolerability measures, which have no formal efficacy test, so there is no met or missed result. The company reports that side effects were mild to moderate and that no dissociation, sedation or psychosis-like symptoms were seen. Effects on depression scores were exploratory. The figures come from the company's press release.

Reported efficacy

Incidence of treatment-related adverse events (AEs) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal orthostatic blood pressure (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal heart rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal blood oxygen saturation (pulse oximetry) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal respiratory rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal body temperature (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal 12-lead electrocardiogram (ECG) parameters (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal hematologic findings (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal serum chemistry test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine cytologic findings (Baseline (prior to dosing) and the End of Study (Day 36) visit); Incidence and severity of dissociative symptoms assessed by Clinician Administered Dissociative States Scale (CADSS) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of treatment-emergent sedation assessed by Modified Observer's Assessment of Alertness/ Sedation (MOAA/S) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of potential withdrawal symptoms assessed by Physician Withdrawal Checklist; 20-item (PWC-20) (Two weeks after last investigational product administration and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of suicide ideation assessed by Columbia Suicide Severity Rating Scale (C-SSRS) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of four-item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination); Injection site tolerability based on injection site grading scale (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site pain visual analog scale (VAS) (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site evaluation for potential reactions and evidence of removal (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit): Primary, safety and tolerability (no formal efficacy test): treatment-related adverse events were mild to moderate in severity, and no dissociation, sedation or psychosis-like symptoms were observed. (not_applicable)

Result source: NCT06965569

Esketamine (CLE-100)

Developed by Clexio Biosciences

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT04103892 · Phase 2 · completed

The study randomized 146 participants overall, including 130 in the main Part B comparison, to double-blind CLE-100 or placebo alongside standard antidepressant treatment. Its clinical MADRS primary endpoint was missed: the improvement with CLE-100 was not significantly different from placebo (p=0.46), so the trial provides well-controlled but inconclusive evidence.

Reported efficacy

Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) (missed)

Result source: NCT06340958

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALA-3000Esketamine (CLE-100)
MADRS, change (acute)—Not reported-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

ALA-3000
—Not reported
Esketamine (CLE-100)
-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892

CGI-S, change (acute)

ALA-3000
—Not reported
Esketamine (CLE-100)
—Not reported

MADRS response

ALA-3000
—Not reported
Esketamine (CLE-100)
—Not reported

MADRS remission

ALA-3000
—Not reported
Esketamine (CLE-100)
—Not reported

Relapse (% of patients)

ALA-3000
—Not reported
Esketamine (CLE-100)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALA-3000: no structured comparison results are available for Major Depressive Disorder.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ALA-3000: 0 of 4 rows · Esketamine (CLE-100): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEsketamine (CLE-100)
Dropout rate
7.7%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
8.3%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Discontinued due to AEs
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
8%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Serious AEs
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
2%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Most frequent reported AEs
dizziness 30.8% (placebo 0%)
somnolence 15.4% (placebo 0%)
alanine aminotransferase increased 7.7% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
dizziness 13.9% (placebo 0%)
headache 12.5% (placebo 0%)
somnolence 11.1% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
dizziness 18% (placebo 4.1%)
nausea 18% (placebo 0%)
headache 12% (placebo 2%)
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Esketamine (CLE-100)

MADRS -10.72 vs -9.46 placebo score @ 4.14wk
absolute change · score
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
-12.96 vs -7.68 placebo score @ 4.14wk
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-11.66 vs -8.7 placebo score @ 4.14wk
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALA-3000's landscape · Esketamine (CLE-100)'s landscape